留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

真实世界研究在慢性伤口领域的研究进展

陈泠西 贾赤宇 何岩

陈泠西, 贾赤宇, 何岩. 真实世界研究在慢性伤口领域的研究进展[J]. 中华烧伤与创面修复杂志, 2022, 38(3): 291-295. DOI: 10.3760/cma.j.cn501120-20210121-00031.
引用本文: 陈泠西, 贾赤宇, 何岩. 真实世界研究在慢性伤口领域的研究进展[J]. 中华烧伤与创面修复杂志, 2022, 38(3): 291-295. DOI: 10.3760/cma.j.cn501120-20210121-00031.
Chen LX,Jia CY,He Y.Research advances of real world study in the field of chronic wound[J].Chin J Burns Wounds,2022,38(3):291-295.DOI: 10.3760/cma.j.cn501120-20210121-00031.
Citation: Chen LX,Jia CY,He Y.Research advances of real world study in the field of chronic wound[J].Chin J Burns Wounds,2022,38(3):291-295.DOI: 10.3760/cma.j.cn501120-20210121-00031.

真实世界研究在慢性伤口领域的研究进展

doi: 10.3760/cma.j.cn501120-20210121-00031
基金项目: 

福建省自然科学基金 2019J01011

厦门大学附属翔安医院科研启动项目 PM201809170010

详细信息
    通讯作者:

    贾赤宇,Email:jiachiyu@qq.com

Research advances of real world study in the field of chronic wound

Funds: 

Natural Science Foundation of Fujian Province of China 2019J01011

Starting Package of Xiang'an Hospital of Xiamen University PM201809170010

More Information
    Corresponding author: Jia Chiyu, Email: jiachiyu@qq.com
  • 摘要: 近年来,作为随机对照试验(RCT)的有力补充手段,真实世界研究(RWS)得到越来越多的关注。但是在慢性伤口领域,大多数患者的病情复杂,RCT的严格纳入和排除标准缺乏实际应用价值。RWS在临床医疗实践、药物与医疗器械监管和卫生技术评估等方面提供了更接近真实医疗环境的数据,但RWS也存在一些待解决的问题,如诊断标准未统一、研究终点不清等。此外,我国慢性伤口领域的RWS似乎还未真正开始,各级机构需要共同努力以推进RWS的发展。

     

  • 参考文献(34)

    [1] ShermanRE,AndersonSA,Dal PanGJ,et al.Real-world evidence-what is it and what can it tell us?[J].N Engl J Med,2016,375(23):2293-2297.DOI: 10.1056/NEJMsb1609216.
    [2] NashP,KirkhamB,OkadaM,et al.Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial[J].Lancet,2017,389(10086):2317-2327.DOI: 10.1016/S0140-6736(17)31429-0.
    [3] EichlerHG,Bloechl-DaumB,BroichK,et al.Data rich, information poor: can we use electronic health records to create a learning healthcare system for pharmaceuticals?[J].Clin Pharmacol Ther,2019,105(4):912-922.DOI: 10.1002/cpt.1226.
    [4] MielkeD,RohdeV.Randomized controlled trials-a critical re-appraisal[J].Neurosurg Rev,2021,44(4):2085-2089.DOI: 10.1007/s10143-020-01401-4.
    [5] EvansK.Real world evidence: can we really expect it to have much influence?[J].Drugs Real World Outcomes,2019,6(2):43-45.DOI: 10.1007/s40801-019-0155-3.
    [6] BlondeL, KhuntiK, HarrisSB, et al. Interpretation and impact of real-world clinical data for the practicing clinician[J]. Adv Ther, 2018;35(11):1763-1774. DOI: 10.1007/s12325-018-0805-y.
    [7] NazhaB, YangJC, OwonikokoTK. Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer[J]. Future Oncol, 2021, 17(8): 965-977. DOI: 10.2217/fon-2020-0951.
    [8] SenCK,GordilloGM,RoyS,et al.Human skin wounds: a major and snowballing threat to public health and the economy[J].Wound Repair Regen,2009,17(6):763-771.DOI: 10.1111/j.1524-475X.2009.00543.x.
    [9] HornSD,FifeCE,SmoutRJ,et al.Development of a wound healing index for patients with chronic wounds[J].Wound Repair Regen,2013,21(6):823-832.DOI: 10.1111/wrr.12107.
    [10] DarlingJD,McCallumJC,SodenPA,et al.Predictive ability of the Society for Vascular Surgery Wound, Ischemia, and foot Infection (WIfI) classification system after first-time lower extremity revascularizations[J].J Vasc Surg,2017,65(3):695-704.DOI: 10.1016/j.jvs.2016.09.055.
    [11] RaspovicKM,WukichDK,NaimanDQ,et al.Effectiveness of viable cryopreserved placental membranes for management of diabetic foot ulcers in a real world setting[J].Wound Repair Regen,2018,26(2):213-220.DOI: 10.1111/wrr.12635.
    [12] LaveryLA,FulmerJ,ShebetkaKA,et al.The efficacy and safety of Grafix® for the treatment of chronic diabetic foot ulcers: results of a multi-centre, controlled, randomised, blinded, clinical trial[J].Int Wound J,2014,11(5):554-560.DOI: 10.1111/iwj.12329.
    [13] ShohamY,KriegerY,TamirE,et al.Bromelain-based enzymatic debridement of chronic wounds: a preliminary report[J].Int Wound J,2018,15(5):769-775.DOI: 10.1111/iwj.12925.
    [14] GrayTA,RhodesS,AtkinsonRA,et al.Opportunities for better value wound care: a multiservice, cross-sectional survey of complex wounds and their care in a UK community population[J].BMJ Open,2018,8(3):e019440.DOI: 10.1136/bmjopen-2017-019440.
    [15] YdeniusV, LarsenR, SteinvallI, et al. Impact of hospital type on risk-adjusted, traffic-related 30-day mortality: a population- based registry study[J/OL]. Burns Trauma, 2021,9:tkaa051 [2021-01-21]. https://pubmed.ncbi.nlm.nih.gov/33732745/.DOI: 10.1093/burnst/tkaa051.
    [16] HamburgMA.Advancing regulatory science[J].Science,2011,331(6020):987.DOI: 10.1126/science.1204432.
    [17] Corrigan-CurayJ,SacksL,WoodcockJ.Real-world evidence and real-world data for evaluating drug safety and effectiveness[J].JAMA,2018,320(9):867-868.DOI: 10.1001/jama.2018.10136.
    [18] LuCY.Uncertainties in real-world decisions on medical technologies[J].Int J Clin Pract,2014,68(8):936-940.DOI: 10.1111/ijcp.12434.
    [19] BrainD,TullenersR,LeeX,et al.Cost-effectiveness analysis of an innovative model of care for chronic wounds patients[J].PLoS One,2019,14(3):e0212366.DOI: 10.1371/journal.pone.0212366.
    [20] GuestJF, AyoubN, McIlwraithT, et al. Health economic burden that wounds impose on the National Health Service in the UK[J]. BMJ Open, 2015, 5(12): e009283. DOI: 10.1136/bmjopen-2015-009283.
    [21] GuestJF, AyoubN, McIlwraithT, et al. Health economic burden that different wound types impose on the UK's National Health Service[J]. Int Wound J, 2017, 14(2): 322-330. DOI: 10.1111/iwj.12603.
    [22] GouldL,LiWW.Defining complete wound closure: closing the gap in clinical trials and practice[J].Wound Repair Regen,2019,27(3):201-224.DOI: 10.1111/wrr.12707.
    [23] GilliganAM.Health economics and outcomes research of wound care: overview of methodology[J].Adv Wound Care (New Rochelle),2018,7(11):380-386.DOI: 10.1089/wound.2018.0817.
    [24] WilliamsR,KontopantelisE,BuchanI,et al.Clinical code set engineering for reusing EHR data for research: a review[J].J Biomed Inform,2017,70:1-13.DOI: 10.1016/j.jbi.2017.04.010.
    [25] McDonaldL,LambrelliD,WasiakR,et al.Real-world data in the United Kingdom: opportunities and challenges[J].BMC Med,2016,14(1):97.DOI: 10.1186/s12916-016-0647-x.
    [26] 王弘恺,朱耀,米尔夏提·阿不都热西提,等.泌尿肿瘤基因突变检测结果单中心真实世界研究[J].中华外科杂志,2019,57(6):457-459.DOI: 10.3760/cma.j.issn.0529-5815.2019.06.012.
    [27] 孙梦媛, 赵慧, 王玉兰, 等. 甲状腺乳头状癌术后复发相关因素的真实世界研究 [J]. 临床医学进展, 2021, 11(1): 357-365. DOI: 10.12677/ACM.2021.111051.
    [28] CarterMJ,FifeCE,WalkerD,et al.Estimating the applicability of wound care randomized controlled trials to general wound-care populations by estimating the percentage of individuals excluded from a typical wound-care population in such trials[J].Adv Skin Wound Care,2009,22(7):316-324.DOI: 10.1097/01.ASW.0000305486.06358.e0.
    [29] van RijswijkL,M.EvidenceGray, research, and practiceclinical: a patient-centered framework for progress in wound care[J].J Wound Ostomy Continence Nurs,2012,39(1):35-44.DOI: 10.1097/WON.0b013e3182383f31.
    [30] 任燕,梁远波,刘密密,等.构建博鳌乐城创新药械真实世界数据研究体系:基于我国首个使用境内真实世界数据获批上市的医疗器械研究的探讨[J].中国循证医学杂志,2020,20(10):1117-1123.DOI: 10.7507/1672-2531.202007133.
    [31] 孙鑫,谭婧,王雯,等.建立真实世界数据与研究技术规范,促进中国真实世界证据的生产与使用[J].中国循证医学杂志,2019,19(7):755-762.
    [32] 李雪迎,沙若琪,姚晨,等.面向真实世界数据的临床研究数据治理模式选择[J].中国循证医学杂志,2020,20(10):1150-1156.DOI: 10.7507/1672-2531.202003122.
    [33] OlsenLA, AisnerD, McGinnisJMichael.The learning healthcare system[M].Washington (DC): National Academies Press (US), 2007.
    [34] SerenaTE,FifeCE,EckertKA,et al.A new approach to clinical research: integrating clinical care, quality reporting, and research using a wound care network-based learning healthcare system[J].Wound Repair Regen,2017,25(3):354-365.DOI: 10.1111/wrr.12538.
  • 表1  真实世界研究的主要类型

    研究类型特点优点不足应用场景举例
    前瞻性队列研究根据研究对象暴露状态决定分组,前瞻性观察一定时间后得到感兴趣结果单个研究可得到多个结果,清楚表明暴露于结果的先后顺序,促进罕见暴露研究,确定发病率的最佳方法成本高昂而耗时,不适合罕见疾病及长潜伏期疾病的研究收集全国吸烟与不吸烟的糖尿病患者,跟踪数年后,确定他们是否以及何时发生糖尿病足
    回顾性队列研究根据过去某一段时间研究对象的暴露状况对其进行分组,根据已有的数据追溯感兴趣结果相较于前瞻性队列研究更加省时省力存在选择偏倚,数据缺失观察伤口中心在过去10年间使用超声清创术与外科器械清创处理下肢慢性伤口后,伤口愈合率及医疗花费的差异
    病例对照研究根据感兴趣的结果选择研究对象,回顾每个研究对象的情况成本低而高效,适用于罕见疾病及长潜伏期疾病研究,生成假设存在选择偏倚、回忆偏倚,难以做出因果关系推断收集下肢静脉溃疡患者住院病历,分为截肢组与非截肢组,分析确定截肢相关危险因素
    横断面研究仅在某一个时间点或很短时间进行的研究,不考虑感兴趣的结果快速且便宜,确定患病率的最佳方法,可研究多个结局不能有效地研究罕见病症,不能区分因果关系调查2019年全国慢性伤口的患病率
    病例报告报告单个患者接受某种诊疗措施产生的某种结果识别新疾病或新症状,检测新药的不良反应或潜在用途,产生假设不能做因果推断,不具有可推广性,严重的发表偏倚手部烧伤瘢痕引起恶性黑色素瘤的病例报告
    病例系列研究一段时间内对多个病例报告的集合描述分析优点同病例报告不足同病例报告回顾性分析A型肉毒毒素治疗3例慢性伤口病例,评估20周伤口愈合率及伤口愈合时间
    实用性RCT在日常卫生保健环境中纳入研究对象,随机分组后测量干预效果可同时比较多种干预措施的优点和不足,允许研究对象的异质性,增加了实验结果的外推性,相对较低的研究成本;可用于罕见疾病的研究不能评价某项干预措施对各组患者的效果纳入真实世界伤口门诊的糖尿病溃疡患者,不排除重症或合并症患者,使用新型敷料或常规换药处理,12周后确定伤口愈合率差异
    基于注册登记研究的RCT根据注册登记处的患者信息,纳入研究对象,随机分组后测量干预效果优点同实用性RCT不足同实用性RCT借助美国慢性伤口登记处,筛选慢性下肢溃疡患者,利用在线工具将其随机分为负压伤口疗法组和标准治疗组,分析一段时间后2组患者治疗满意度及伤口愈合率的差别
    非随机同期对照试验医师根据病情或有关因素人为纳入试验组或对照组,并进行同期对照试验可行性好,患者依从性佳,不存在伦理道德问题实验组与对照组一定程度上缺乏可比性,难以应用盲法,存在选择偏倚与测量偏倚根据重症下肢溃疡患者病情和意愿选择膝上截肢或膝下截肢,随访5年内病死率差异
    注:RCT为随机对照试验
    下载: 导出CSV
  • 加载中
表(1)
计量
  • 文章访问数:  394
  • HTML全文浏览量:  87
  • PDF下载量:  54
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-01-21

目录

    /

    返回文章
    返回